BRPI0412591A - antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destes - Google Patents
antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destesInfo
- Publication number
- BRPI0412591A BRPI0412591A BRPI0412591-6A BRPI0412591A BRPI0412591A BR PI0412591 A BRPI0412591 A BR PI0412591A BR PI0412591 A BRPI0412591 A BR PI0412591A BR PI0412591 A BRPI0412591 A BR PI0412591A
- Authority
- BR
- Brazil
- Prior art keywords
- factors
- antibiotic
- pharmaceutically acceptable
- acceptable salts
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/195—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Polymers & Plastics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Husbandry (AREA)
- Oncology (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03016306 | 2003-07-18 | ||
PCT/EP2004/007658 WO2005014628A1 (en) | 2003-07-18 | 2004-07-12 | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof. |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0412591A true BRPI0412591A (pt) | 2006-09-19 |
Family
ID=34130026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0412591-6A BRPI0412591A (pt) | 2003-07-18 | 2004-07-12 | antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destes |
Country Status (12)
Country | Link |
---|---|
US (1) | US7307057B2 (pt) |
EP (1) | EP1646646B1 (pt) |
JP (1) | JP4163737B2 (pt) |
AR (1) | AR046809A1 (pt) |
AT (1) | ATE356143T1 (pt) |
BR (1) | BRPI0412591A (pt) |
CA (1) | CA2529124C (pt) |
DE (1) | DE602004005203T2 (pt) |
ES (1) | ES2281808T3 (pt) |
MX (1) | MXPA06000691A (pt) |
TW (1) | TWI340167B (pt) |
WO (1) | WO2005014628A1 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7351687B2 (en) * | 2003-07-18 | 2008-04-01 | Vicuron Pharmaceuticals, Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
US7319088B2 (en) | 2003-07-18 | 2008-01-15 | Vicuron Pharmaceuticals Inc. | Antibiotic 107891, its factors A1 and A2, pharmaceutically acceptable salts and compositions, and use thereof |
WO2006075988A1 (en) | 2005-01-12 | 2006-07-20 | Vicuron Pharmaceuticals Inc. | Antibiotic 107891, its factors a1 and a2, pharmaceutically acceptable salts and compositions, and use thereof |
RS52513B (en) * | 2005-01-12 | 2013-04-30 | Sentinella Pharmaceuticals Inc. ("Sentinella") | ANTIBIOTIC 107891, ITS FACTORS, PHARMACEUTICALALLY ACCEPTABLE SALTS AND MIXTURES, AND THEIR USE |
GB0600928D0 (en) | 2006-01-17 | 2006-02-22 | Novacta Biosystems Ltd | Improvements relating to lantibiotics |
GB0714030D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | The use of type-B lantibiotic-based compounds having antimicrobial activity |
GB0714029D0 (en) | 2007-07-18 | 2007-08-29 | Novacta Biosystems Ltd | Lantibiotic-based compounds having antimicrobial activity |
US8609367B2 (en) | 2007-08-03 | 2013-12-17 | Sentinella Pharmaceuticals, Inc. | Genes and proteins for the biosynthesis of the lantibiotic 107891 |
DK2387580T3 (da) | 2009-01-14 | 2014-10-13 | Novacta Biosystems Ltd | Deoxyactagardinderivater |
CN102388060B (zh) | 2009-02-04 | 2014-09-10 | 诺瓦克塔生物系统有限公司 | 阿肽加定衍生物 |
GB201001688D0 (en) | 2010-02-02 | 2010-03-17 | Novacta Biosystems Ltd | Compounds |
GB201013513D0 (en) | 2010-08-11 | 2010-09-22 | Novacta Biosystems Ltd | Formulations |
JP2016501232A (ja) | 2012-11-30 | 2016-01-18 | ナイコンス,エセエッレエレNaicons,Srl | 新規ランチビオティック誘導体およびその調製プロセス |
US11174288B2 (en) | 2016-12-06 | 2021-11-16 | Northeastern University | Heparin-binding cationic peptide self-assembling peptide amphiphiles useful against drug-resistant bacteria |
BR112020000196A2 (pt) | 2017-07-07 | 2020-07-07 | Epicentrx, Inc. | composições para administração parenteral de agentes terapêuticos |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59198982A (ja) | 1983-04-28 | 1984-11-10 | Meiji Seika Kaisha Ltd | 新抗生物質sf−2240物質およびその製造法 |
EP0592835A3 (en) | 1992-09-23 | 1995-03-15 | Bristol Myers Squibb Co | Antibiotics of type BU-4803T. |
US6551591B1 (en) * | 2001-09-07 | 2003-04-22 | Essential Therapeutics, Inc. | Antibiotics from microbispora |
-
2004
- 2004-07-12 BR BRPI0412591-6A patent/BRPI0412591A/pt not_active IP Right Cessation
- 2004-07-12 EP EP04740916A patent/EP1646646B1/en not_active Not-in-force
- 2004-07-12 DE DE602004005203T patent/DE602004005203T2/de active Active
- 2004-07-12 JP JP2006520724A patent/JP4163737B2/ja not_active Expired - Fee Related
- 2004-07-12 AT AT04740916T patent/ATE356143T1/de not_active IP Right Cessation
- 2004-07-12 MX MXPA06000691A patent/MXPA06000691A/es active IP Right Grant
- 2004-07-12 US US10/521,336 patent/US7307057B2/en active Active
- 2004-07-12 CA CA2529124A patent/CA2529124C/en not_active Expired - Fee Related
- 2004-07-12 WO PCT/EP2004/007658 patent/WO2005014628A1/en active IP Right Grant
- 2004-07-12 ES ES04740916T patent/ES2281808T3/es active Active
- 2004-07-15 TW TW093121124A patent/TWI340167B/zh not_active IP Right Cessation
- 2004-07-19 AR ARP040102548A patent/AR046809A1/es active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US7307057B2 (en) | 2007-12-11 |
EP1646646A1 (en) | 2006-04-19 |
MXPA06000691A (es) | 2006-04-11 |
AR046809A1 (es) | 2005-12-28 |
ES2281808T3 (es) | 2007-10-01 |
EP1646646B1 (en) | 2007-03-07 |
JP4163737B2 (ja) | 2008-10-08 |
WO2005014628A1 (en) | 2005-02-17 |
DE602004005203D1 (de) | 2007-04-19 |
CA2529124A1 (en) | 2005-02-17 |
US20060183673A1 (en) | 2006-08-17 |
TWI340167B (en) | 2011-04-11 |
JP2007525479A (ja) | 2007-09-06 |
CA2529124C (en) | 2011-02-08 |
TW200510541A (en) | 2005-03-16 |
ATE356143T1 (de) | 2007-03-15 |
DE602004005203T2 (de) | 2007-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0412591A (pt) | antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e uso destes | |
BRPI0519942A2 (pt) | antibiótico 107891, seus fatores a1 e a2, sais e composições farmaceuticamente aceitáveis e usos dos mesmos | |
Giacometti et al. | In-vitro activity and killing effect of polycationic peptides on methicillin-resistant Staphylococcus aureus and interactions with clinically used antibiotics | |
Giamarellou et al. | In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa | |
Sader et al. | Antimicrobial activity of daptomycin against multidrug-resistant Gram-positive strains collected worldwide | |
Brook | Failure of penicillin to eradicate group A beta-hemolytic streptococci tonsillitis: causes and management. | |
Kitazaki et al. | In vitro synergistic activities of cefazolin and nisin A against mastitis pathogens | |
Fan et al. | Antibacterial activity of the recombinant antimicrobial peptide Ib-AMP4 from Impatiens balsamina and its synergy with other antimicrobial agents against drug resistant bacteria | |
Huang et al. | Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan | |
Qi et al. | Pharmacodynamics of linezolid-plus-fosfomycin against vancomycin-susceptible and-resistant Enterococci in vitro and in vivo of a galleria mellonella larval infection model | |
Giacometti et al. | In vitro activity and killing effect of the synthetic hybrid cecropin A–melittin peptide CA (1–7) M (2–9) NH2 on methicillin-resistant nosocomial isolates of Staphylococcus aureus and interactions with clinically used antibiotics | |
Fuursted | Comparative killing activity and postantibiotic effect of streptomycin combined with ampicillin, ciprofloxacin, imipenem, piperacillin or vancomycin against strains of Streptococcus faecalis and Streptococcus faecium | |
Oli et al. | Actinomycetes in medical and pharmaceutical industries | |
BRPI0519325A2 (pt) | compostos, complexo antibiàtico 107891, seus fatores a1 e a2, sais farmaceuticamente aceitÁveis, processo para produzir composiÇço e uso do mesmo | |
Callapina et al. | Systemic and intracerebral infections of mice with Listeria monocytogenes successfully treated with linezolid | |
Mar Soe et al. | Ethyl gallate as a combination drug can overcome resistance in MRSA | |
UA87546C2 (ru) | Антибиотик 107891, его факторы а1 и а2, фармацевтически приемлемые соли, композиция и их использование | |
Giacometti et al. | In vitro activity and killing effect of uperin 3.6 against gram-positive cocci isolated from immunocompromised patients | |
Sorlozano et al. | Activity of daptomycin against multiresistant clinical isolates of Staphylococcus aureus and Streptococcus agalactiae | |
Sader et al. | In vitro activity and potency of the novel oxazolidinone MRX-I tested against contemporary clinical isolates of Gram-positive bacteria | |
Surve et al. | Toxicity of oxazolidinone linezolid on pathogenic microorganism Listeria ivanovii | |
Beier et al. | Disinfectants (biocides) used in animal production: antimicrobial resistance considerations | |
Van Der Auwera et al. | Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously | |
US20240041976A1 (en) | Composition and use | |
BR0214494A (pt) | Fatores antibióticos ge 81112 a, b, b1, seus sais e composições farmaceuticamente aceitáveis e uso dos mesmos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25A | Requested transfer of rights approved |
Owner name: NAICONS S.C.A.R.L. (IT) Free format text: TRANSFERIDO DE: VICURON PHARMACEUTICALS INC. |
|
B25A | Requested transfer of rights approved |
Owner name: NEXTHERA BIOSCIENCES S.R.L. (IT) Free format text: TRANSFERIDO DE: NAICONS S.C.A.R.L. |
|
B25A | Requested transfer of rights approved |
Owner name: SENTINELLA PHARMACEUTICALS, INC. (US) Free format text: TRANSFERIDO DE: NEXTHERA BIOSCIENCES S.R.L. |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: PAGAR RESTAURACAO. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B15K | Others concerning applications: alteration of classification |
Ipc: C12R 1/01 (2006.01), A23K 20/195 (2016.01), C07K 1 |